We are live on ! Find out more
PCVX icon

Vaxcyte

202 hedge funds and large institutions have $5.17B invested in Vaxcyte in 2023 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 86 increasing their positions, 58 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 16

48% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 58

28% more call options, than puts

Call options by funds: $2.77M | Put options by funds: $2.17M

18% more funds holding in top 10

Funds holding in top 10: 1113 (+2)

3% more funds holding

Funds holding: 197202 (+5)

1.26% more ownership

Funds ownership: 106.77%108.03% (+1.3%)

3% more capital invested

Capital invested by funds: $5B → $5.17B (+$171M)

Holders
202
Holders Change
+5
Holders Change %
+2.54%
% of All Funds
3.21%
Holding in Top 10
13
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+18.18%
% of All Funds
0.21%
New
24
Increased
86
Reduced
58
Closed
16
Calls
$2.77M
Puts
$2.17M
Net Calls
+$607K
Net Calls Change
+$19.2M
Name Holding Trade Value Shares
Change
Change in
Stake
TI
101
Trexquant Investment
Connecticut
$2.21M +$1.88M +38,058 +722%
CUAMC
102
China Universal Asset Management Company
China
$2.16M +$58.3K +1,182 +3%
AR
103
Advisory Research
Illinois
$2.1M +$322K +6,537 +19%
Dimensional Fund Advisors
104
Dimensional Fund Advisors
Texas
$2.08M +$1.49M +30,157 +286%
Envestnet Asset Management
105
Envestnet Asset Management
Illinois
$2.01M +$844K +17,117 +77%
AGP
106
Artia Global Partners
Florida
$1.97M
BBHC
107
Brown Brothers Harriman & Co
New York
$1.94M
Prudential Financial
108
Prudential Financial
New Jersey
$1.83M -$4.16M -84,332 -70%
LCG
109
Lisanti Capital Growth
New York
$1.78M -$4.82M -97,765 -74%
First Trust Advisors
110
First Trust Advisors
Illinois
$1.67M -$133K -2,691 -8%
BG
111
Bellevue Group
Switzerland
$1.55M +$222K +4,500 +17%
GC
112
Guggenheim Capital
Illinois
$1.54M +$60.4K +1,225 +4%
PA
113
Profund Advisors
Maryland
$1.47M -$105K -2,122 -7%
EAM
114
Erste Asset Management
Austria
$1.46M
SG Americas Securities
115
SG Americas Securities
New York
$1.43M +$1.38M +27,980 New
BFM
116
Boothbay Fund Management
New York
$1.42M +$127K +2,575 +10%
State Board of Administration of Florida Retirement System
117
State Board of Administration of Florida Retirement System
Florida
$1.36M +$33.1K +670 +3%
CCIA
118
Campbell & Co Investment Adviser
Maryland
$1.34M +$276K +5,594 +27%
Alyeska Investment Group
119
Alyeska Investment Group
Illinois
$1.27M
AAA
120
Affinity Asset Advisors
New York
$1.27M +$546K +11,077 +80%
AG
121
Algert Global
California
$1.26M +$138K +2,790 +13%
Citadel Advisors
122
Citadel Advisors
Florida
$1.13M +$1.09M +22,106 New
Susquehanna International Group
123
Susquehanna International Group
Pennsylvania
$1.11M -$280K -5,684 -21%
Principal Financial Group
124
Principal Financial Group
Iowa
$1.1M -$25.9K -524 -2%
TRSOTSOK
125
Teachers Retirement System of the State of Kentucky
Kentucky
$1.1M

PCVX Hedge Fund Activity: Q3 2023 in Review

202 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q3 2023, worth a combined $5.17B — up 3.4% from $5B a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new PCVX positions and 16 closed out — a net gain of 8 holders — while 86 added to existing stakes and 58 trimmed.

The largest buyer was Westfield Capital Management, opening a new position worth an estimated $49.5M. The largest seller was Millennium Management, cutting an estimated $31.1M.

  • 202 institutional investors held Vaxcyte (PCVX) as of Q3 2023, up from 197 in Q2 2023.
  • Funds reported $5.17B of Vaxcyte stock for Q3 2023, up 3.4% quarter-over-quarter.
  • 24 funds opened new Vaxcyte positions in Q3 2023 and 16 closed out, a net change of +8 holders.
  • The largest Vaxcyte buyer in Q3 2023 was Westfield Capital Management, an estimated $49.5M added.
  • The largest Vaxcyte seller in Q3 2023 was Millennium Management, an estimated $31.1M sold.

Based on aggregated 13F filings for Q3 2023.